SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response
Status:
NOT_YET_RECRUITING
Trial end date:
2030-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, multicenter clinical study to evaluate the efficacy and safety of SHR-A1811 in early or locally advanced HER2-positive breast cancer patients with suboptimal response to neoadjuvant regimen. Patients who were determined by the researchers to have poor therapeutic effect will switch to SHR-A1811.